“…The immunogenicity and safety of MenB-FHbp has thus far been evaluated in 11 published clinical studies wherein more than 15,000 adolescents and young adults received the vaccine. 35 These studies evaluated 2-and 3-dose schedules, long-term immunogenicity, booster dose responses, and coadministration with vaccines commonly given to adolescents, including MenACWY-D, Tdap (Adacel®, Sanofi Pasteur Inc., Swiftwater, PA, USA), 4vHPV (Gardasil®, Merck & Co, Inc., Whitehouse Station, NJ, USA), and Tdap/IPV (Repevax®, Sanofi Pasteur, Lyon, France) vaccines. [36][37][38] Clinical data supporting the MenB-FHbp 2-dose schedule were from a phase 2 randomized clinical study in healthy adolescents aged 11-18 y that evaluated multiple schedules: 2 doses (administered at 0 and 2 months, 0 and 4 months, or 0 and 6 months) or 3 doses (at 0, 1, and 6 months or 0, 2, and 6 months).…”